Celldex Therapeutics, Inc. (CLDX) stock
CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$28.83+0.30 (+1.05%)
Close on Nov 13, 2026Market cap $2.26BP/E –Yield –
Celldex Therapeutics cash
Cash and short-term investments held at the end of each period.
Celldex Therapeutics's cash was $650.32M at Sep 30, 2026. For fiscal 2025 it was $518.57M, down 28.5% from the year before. Over ten years it grew 6.0% a year on average. The highest annual figure on record is $725.28M in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $518.57M | -28.5% |
| FY2024 | Dec 31, 2024 | $725.28M | +71.2% |
| FY2023 | Dec 31, 2023 | $423.60M | +38.9% |
| FY2022 | Dec 31, 2022 | $304.95M | -25.3% |
| FY2021 | Dec 31, 2021 | $408.25M | +110.0% |
| FY2020 | Dec 31, 2020 | $194.42M | +202.0% |
| FY2019 | Dec 31, 2019 | $64.38M | -31.5% |
| FY2018 | Dec 31, 2018 | $94.02M | -32.6% |
| FY2017 | Dec 31, 2017 | $139.43M | -26.5% |
| FY2016 | Dec 31, 2016 | $189.78M | -34.5% |
| FY2015 | Dec 31, 2015 | $289.89M | +44.2% |
| FY2014 | Dec 31, 2014 | $201.04M | -33.6% |
| FY2013 | Dec 31, 2013 | $302.98M | +260.9% |
| FY2012 | Dec 31, 2012 | $83.96M | +57.5% |
| FY2011 | Dec 31, 2011 | $53.31M | -12.7% |
| FY2010 | Dec 31, 2010 | $61.10M | +7.2% |
| FY2009 | Dec 31, 2009 | $57.00M | +28.8% |
| FY2008 | Dec 31, 2008 | $44.26M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $650.32M | +11.5% |
| Q2 FY2026 | Jun 30, 2026 | $717.59M | +13.8% |
| Q1 FY2026 | Mar 31, 2026 | $451.46M | -32.9% |
| Q4 FY2025 | Dec 31, 2025 | $518.57M | -28.5% |
| Q3 FY2025 | Sep 30, 2025 | $583.22M | -22.9% |
| Q2 FY2025 | Jun 30, 2025 | $630.34M | -21.4% |
| Q1 FY2025 | Mar 31, 2025 | $673.29M | -18.3% |
| Q4 FY2024 | Dec 31, 2024 | $725.28M | +71.2% |
| Q3 FY2024 | Sep 30, 2024 | $756.00M | +221.2% |
| Q2 FY2024 | Jun 30, 2024 | $802.32M | +217.5% |
| Q1 FY2024 | Mar 31, 2024 | $823.85M | +195.9% |
| Q4 FY2023 | Dec 31, 2023 | $423.60M | +38.9% |
| Q3 FY2023 | Sep 30, 2023 | $235.35M | -27.2% |
| Q2 FY2023 | Jun 30, 2023 | $252.70M | -29.2% |
| Q1 FY2023 | Mar 31, 2023 | $278.39M | -26.8% |
| Q4 FY2022 | Dec 31, 2022 | $304.95M | -25.3% |
| Q3 FY2022 | Sep 30, 2022 | $323.47M | -23.5% |
| Q2 FY2022 | Jun 30, 2022 | $356.82M | +117.5% |
| Q1 FY2022 | Mar 31, 2022 | $380.47M | +116.1% |
| Q4 FY2021 | Dec 31, 2021 | $408.25M | +110.0% |
| Q3 FY2021 | Sep 30, 2021 | $423.09M | +112.0% |
| Q2 FY2021 | Jun 30, 2021 | $164.04M | -20.7% |
| Q1 FY2021 | Mar 31, 2021 | $176.08M | +227.8% |
| Q4 FY2020 | Dec 31, 2020 | $194.42M | +202.0% |
| Q3 FY2020 | Sep 30, 2020 | $199.59M | +173.7% |
| Q2 FY2020 | Jun 30, 2020 | $206.92M | +154.4% |
| Q1 FY2020 | Mar 31, 2020 | $53.72M | -36.8% |
| Q4 FY2019 | Dec 31, 2019 | $64.38M | -31.5% |
| Q3 FY2019 | Sep 30, 2019 | $72.92M | -31.0% |
| Q2 FY2019 | Jun 30, 2019 | $81.34M | -28.7% |
| Q1 FY2019 | Mar 31, 2019 | $85.07M | -31.0% |
| Q4 FY2018 | Dec 31, 2018 | $94.02M | -32.6% |
| Q3 FY2018 | Sep 30, 2018 | $105.62M | -24.8% |
| Q2 FY2018 | Jun 30, 2018 | $114.01M | -26.0% |
| Q1 FY2018 | Mar 31, 2018 | $123.25M | -26.2% |
| Q4 FY2017 | Dec 31, 2017 | $139.43M | -26.5% |
| Q3 FY2017 | Sep 30, 2017 | $140.53M | – |
| Q2 FY2017 | Jun 30, 2017 | $153.98M | – |
| Q1 FY2017 | Mar 31, 2017 | $167.02M | – |
| Q4 FY2016 | Dec 31, 2016 | $189.78M | – |
See a number that looks wrong?